NasdaqCM - Nasdaq Real Time Price USD

MEI Pharma, Inc. (MEIP)

Compare
2.7000 0.0000 (0.00%)
At close: December 13 at 4:00:01 PM EST
2.6300 -0.07 (-2.59%)
After hours: December 13 at 5:00:16 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
--
65,297.0000
48,816.0000
40,697.0000
34,796.0000
Cost of Revenue
--
--
--
--
1,408.0000
Gross Profit
--
--
--
40,697.0000
33,388.0000
Operating Expense
38,192.0000
39,856.0000
85,580.0000
116,181.0000
93,812.0000
Operating Income
-38,192.0000
25,441.0000
-36,764.0000
-75,484.0000
-60,424.0000
Net Non Operating Interest Income Expense
2,538.0000
3,277.0000
3,345.0000
284.0000
510.0000
Other Income Expense
-10,949.0000
-10,940.0000
1,581.0000
20,746.0000
18,608.0000
Pretax Income
-46,603.0000
17,778.0000
-31,838.0000
-54,454.0000
-41,306.0000
Tax Provision
--
--
--
--
8.0000
Net Income Common Stockholders
-46,603.0000
17,778.0000
-31,838.0000
-54,454.0000
-41,314.0000
Average Dilution Earnings
-14,357.0000
--
--
-8,046.0000
-27,394.0000
Diluted NI Available to Com Stockholders
-46,603.0000
17,778.0000
-31,838.0000
-62,500.0000
-68,708.0000
Basic EPS
-6.99
2.67
-4.78
-8.75
-7.40
Diluted EPS
-6.99
2.67
-4.78
-9.99
-12.00
Basic Average Shares
6,663.0000
6,663.0000
6,663.0000
6,224.0000
5,626.3500
Diluted Average Shares
6,663.0000
6,663.0000
6,663.0000
6,257.0000
5,724.0500
Total Operating Income as Reported
-49,091.0000
14,542.0000
-36,764.0000
-75,484.0000
-60,424.0000
Total Expenses
38,192.0000
39,856.0000
85,580.0000
116,181.0000
95,220.0000
Net Income from Continuing & Discontinued Operation
-46,603.0000
17,778.0000
-31,838.0000
-54,454.0000
-41,314.0000
Normalized Income
-35,704.0000
26,388.2100
-33,441.0000
-75,206.0000
-59,436.0000
Interest Income
2,538.0000
3,277.0000
3,345.0000
284.0000
510.0000
Net Interest Income
2,538.0000
3,277.0000
3,345.0000
284.0000
510.0000
EBIT
-38,192.0000
25,441.0000
-36,764.0000
-75,484.0000
-60,424.0000
EBITDA
-37,528.0000
25,824.0000
-36,378.0000
-75,158.0000
-60,139.0000
Reconciled Cost of Revenue
--
--
--
--
1,408.0000
Reconciled Depreciation
664.0000
383.0000
386.0000
326.0000
285.0000
Net Income from Continuing Operation Net Minority Interest
-46,603.0000
17,778.0000
-31,838.0000
-54,454.0000
-41,314.0000
Total Unusual Items Excluding Goodwill
-10,899.0000
-10,899.0000
1,603.0000
20,752.0000
18,122.0000
Total Unusual Items
-10,899.0000
-10,899.0000
1,603.0000
20,752.0000
18,122.0000
Normalized EBITDA
-26,629.0000
36,723.0000
-37,981.0000
-95,910.0000
-78,261.0000
Tax Rate for Calcs
--
0.0002
--
--
--
Tax Effect of Unusual Items
--
-2,288.7900
--
--
--
6/30/2021 - 12/18/2003

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PIRS Pieris Pharmaceuticals, Inc.
13.60
-15.58%
 
ANTX AN2 Therapeutics, Inc.
1.4300
-3.38%
 
ELVN Enliven Therapeutics, Inc.
23.15
+0.65%
 
SLNO Soleno Therapeutics, Inc.
46.71
+0.93%
 
17R.BE Travere Therapeutics Inc
16.40
-4.65%
 
TRRI Alzex Neuropharma Inc.
0.2400
0.00%
 
PMCB PharmaCyte Biotech, Inc.
1.7200
+2.99%
 
HTDS Hard to Treat Diseases Inc.
0.0000
0.00%
 
TRAW Traws Pharma, Inc.
4.6501
-9.00%
 
CRIS Curis, Inc.
3.5700
-4.03%